The landscape of preclinical drug development is undergoing a paradigm shift driven by the need for more human-relevant evidence and a global regulatory movement toward ethical safety testing.
The passage of the FDA Modernization Act 2.0 in December 2022 was a watershed moment that removed the statutory requirement for animal studies to be the sole path to first-in-human clinical trials (Najjar et al., 2023).
This legislation explicitly permits the use of Non-Animal Models (NAMs), such as cell-based assays and microphysiological systems (MPS), synergistically paired with pharmacometrics, specifically Physiologically Based Pharmacokinetic (PBPK) and Pharmacokinetic/Pharmacodynamic (PK/PD) modeling. Together, these quantitative tools assess drug safety and efficacy when scientifically justified (García, n.d.).
This transition transcends ethical compliance; it addresses the high attrition rates in drug development caused by the poor translational predictivity of traditional animal models (Paliwal et al., 2020; Sun et al., 2022). By relying on mechanistically rich, human-centered approaches driven by Model-Informed Drug Development (MIDD), the industry is entering an era of accelerated, precise, and more reliable predictive toxicology and pharmacology.
Historically, animal testing has been crucial for making go/no-go decisions at major transition points in the drug pipeline. However, safety and efficacy failures remain major causes of attrition in drug discovery, highlighting the limitations of non-human species in mimicking human pathophysiology (Goldring, n.d.). This is especially true for highly targeted therapies, such as cell and gene therapies or advanced biologics, which rely on precise interactions with human-specific receptors and tissue microenvironments that animal models often fail to capture (Santos, n.d.).
NAMs and pharmacometrics bridge this translational gap by utilizing a quantitative, data-driven framework.
Complex cell-based assays that evaluate the biological and toxicological effects of substances at a cellular level, providing the raw parameters (e.g., intrinsic clearance, receptor affinity) needed for computational models.
Often known as organs-on-a-chip, these advanced cellular models mimic human organ interactions. For example, multi-organ chips (e.g., skin-liver-thyroid) can incorporate exposure routes and metabolism, generating highly accurate human-specific data to feed into predictive models (Najjar et al., 2023).
The mathematical engine translating bench data to human predictions: PBPK Modeling, Quantitative Systems Pharmacology (QSP), PK/PD Modeling. These frameworks enable the robust extrapolation of in-vitro concentration-response readouts to in vivo human dose-response predictions, ensuring next-generation risk assessment (NGRA) (Najjar et al., 2023).
Integrates physiological mechanisms (blood flow, organ volumes) with drug-specific chemical properties to predict how a drug will be absorbed, distributed, metabolized, and excreted (ADME) in humans, completely bypassing the need for allometric scaling from animals.
Links to the predicted drug exposure (PK) to the biological response or toxicity (PD) over time.
Evaluates mechanistically how a drug interacts with biological pathways to predict toxic events (Goldring, n.d.).
While the FDA Modernization Act 2.0 is a significant milestone in the United States, it builds upon decades of global precedents anchored by the 3Rs principles: Replacement, Reduction, and Refinement of animal use (Santos, n.d.).
Removal of the legal requirement to conduct animal studies as the sole pathway to human clinical trials. Explicit authorization of NAMs, cell-based assays, MPS, PBPK, and PK/PD when scientifically justified (Najjar et al., 2023).
Europe has been a pioneer in minimizing animal testing, highlighted by the 2013 ban on animal testing for cosmetics. Agencies such as the European Medicines Agency (EMA) actively champion MIDD and are revising guidelines to facilitate the regulatory acceptance of 3R approaches and NAM-generated data (Courtot, n.d.).
The UK recently published an ambitious strategic plan to phase out animal testing, aiming to integrate NAMs and in silico methods systematically across regulatory frameworks (Courtot, n.d.).
The FDA's openness to NAMs signifies that regulatory agencies are receptive to non-animal evidence, provided it is "fit-for-purpose" and scientifically robust (García, n.d.).
Sponsors must transition from purely descriptive assays to mechanistic, model-based approaches. By integrating organoids and PBPK/PD modeling early in the pipeline, developers can simulate clinical scenarios in-silico. This allows teams to identify toxic liabilities, optimize formulation behavior, and accurately predict First-In-Human (FIH) starting doses before progressing to expensive clinical trials (García, n.d.).
The goal of regulatory agencies is not to lower the safety bar but to promote better, mathematically justified science. Sponsors seeking to leverage NAMs must demonstrate the physiological relevance, predictive performance, and validation status of their chosen models (García, n.d.). Early engagement through mechanisms like the FDA’s MIDD Paired Meeting Program or the EMA's Innovation Task Force is critical. Regulators increasingly expect to see how in vitro data inputs into PBPK models to justify safety margins prior to marketing authorization application (MAA) submissions (Courtot, n.d.).
NAMs will complement rather than immediately displace the entirety of the classical biopharmaceutic toolkit. Their implementation requires rigorous standardization to ensure they can credibly replace, reduce, or refine animal studies. Pharmacometrics acts as a crucial bridge translating static in-vitro NAM results into dynamic in vivo human predictions without compromising human safety (García, n.d.).
| Feature | Traditional Animal Models | NAMs + Pharmacometrics (PBPK & PK/PD) |
|---|---|---|
| Physiological Relevance | Limited due to cross-species differences. | High; utilizes human cells, tissues, and exact human physiological parameters. |
| Dose Prediction & Scaling | Relies on empirical allometric scaling; often inaccurate. | Uses mechanistic PBPK modeling for highly accurate human dose predictions. |
| Cost & Throughput | High cost, low throughput, resource intensive. | Decreasing in-vitro costs, rapid in silico throughput capabilities. |
| Mechanism of Action (MoA) | Often observational and descriptive. | Highly mechanistic, linking molecular insights directly to simulated systemic outcomes. |
| Ethical Compliance | High concern; increasingly restricted globally. | Fully aligned with the 3Rs (Replacement, Reduction, Refinement). |
Courtot, L. (n.d.). NAMs In France And Europe: The Current Landscape. Drug Discovery Online. (Posted on 20th March 2026). See article
García, M. A. (25th April 2026). Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments. MDPI. See article
Goldring, C. E. (n.d.). Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety. University of Liverpool Repository. (Deposited on 28th October 2025 ; modified on 23rd May 2026). See article
Najjar, A., Kramer, N., Gardner, I., Hartung, T., & Steger-Hartmann, T. (2023). Editorial: Advances in and applications of predictive toxicology: 2022. Frontiers in Pharmacology, 14. See article
Santos, J. A. (n.d.). New Approach Methods In Practice: Where Are We Today. Drug Discovery Online. (Article posted on the 10th of February 2026). See article
The transition to non-animal methods is underway. Our pharmacometrics teams help position your development program at the forefront of this transformation
Tell us about your programSearch expertise, case studies, publications, resources and more.
